Cardiff Oncology Inc’s filing revealed that its Director PACE GARY W acquired Company’s shares for reported $0.67 million on Jul 30 ’25. In the deal valued at $2.45 per share,275,000 shares were bought. As a result of this transaction, PACE GARY W now holds 1,330,676 shares worth roughly $4.1 million.
Then, PACE GARY W bought 15,000 shares, generating $36,750 in total proceeds. Upon buying the shares at $2.45, the Director now owns 1,345,676 shares.
Noble Capital Markets initiated its Cardiff Oncology Inc [CRDF] rating to an Outperform in a research note published on January 05, 2026; the price target was $12. A number of analysts have revised their coverage, including Ladenburg Thalmann’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Jefferies began covering CRDF with “Hold” recommendation on June 24, 2025. Craig Hallum started covering the stock on September 06, 2024. It rated CRDF as “a Buy”.
Price Performance Review of CRDF
On Monday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock fall -2.84% to $3.08. Over the last five days, the stock has gained 15.79%. Cardiff Oncology Inc shares have fallen nearly -25.06% since the year began. Nevertheless, the stocks have risen 9.61% over the past one year.
How much short interest is there in Cardiff Oncology Inc?
A steep rise in short interest was recorded in Cardiff Oncology Inc stocks on 2025-12-15, growing by 1.31 million shares to a total of 16.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 14.82 million shares. There was a rise of 8.13%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 05, 2022 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
